NeuroDerm Company Profile (NASDAQ:NDRM)

About NeuroDerm (NASDAQ:NDRM)

NeuroDerm logoNeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson's disease, as well as other CNS diseases. The Company's Parkinson's disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages. Its liquid LD/CD and apomorphine formulations include ND0612H, ND0612L and ND0701. It is developing ND0612H for the treatment of patients suffering from severe Parkinson's disease. It is developing ND0612L for the treatment of patients at the moderate stage of Parkinson's disease that can no longer control motor complications with oral levodopa. It has also designed ND0701, which is an apomorphine-based product. ND0701 is for patients suffering from Parkinson's disease, may be used mostly by patients suffering from high motor fluctuations and not responding well to LD/CD.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NDRM
  • CUSIP: N/A
  • Web:
  • Market Cap: $1.02 billion
  • Outstanding Shares: 26,345,000
Average Prices:
  • 50 Day Moving Avg: $38.84
  • 200 Day Moving Avg: $32.05
  • 52 Week Range: $15.20 - $38.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -19.92
  • P/E Growth: -0.83
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.87 per share
  • Price / Book: 7.98
  • EBITDA: ($49,040,000.00)
  • Return on Equity: -38.82%
  • Return on Assets: -36.88%
  • Current Ratio: 17.69%
  • Quick Ratio: 17.69%
  • Average Volume: 807,554 shs.
  • Beta: 0.77
  • Short Ratio: 1.47

Frequently Asked Questions for NeuroDerm (NASDAQ:NDRM)

What is NeuroDerm's stock symbol?

NeuroDerm trades on the NASDAQ under the ticker symbol "NDRM."

How were NeuroDerm's earnings last quarter?

NeuroDerm Ltd. (NASDAQ:NDRM) announced its quarterly earnings data on Thursday, May, 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.13. View NeuroDerm's Earnings History.

When will NeuroDerm make its next earnings announcement?

NeuroDerm is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for NeuroDerm.

Where is NeuroDerm's stock going? Where will NeuroDerm's stock price be in 2017?

8 brokers have issued 1-year price targets for NeuroDerm's shares. Their predictions range from $39.00 to $70.00. On average, they anticipate NeuroDerm's share price to reach $45.86 in the next year. View Analyst Ratings for NeuroDerm.

What are analysts saying about NeuroDerm stock?

Here are some recent quotes from research analysts about NeuroDerm stock:

  • 1. According to Zacks Investment Research, "Neuroderm Ltd. is a clinical-stage pharmaceutical company. It is developing next-generation treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson's disease (PD). Its product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. NeuroDerm Ltd. is headquartered in Rehovot, Israel. " (10/18/2017)
  • 2. Cowen and Company analysts commented, "Neuroderm announced the preliminary Phase II results for ND0612H, and importantly, the initial feedback from our consultants has been very positive. In general, our consultants believe the efficacy looks comparable to Duodopa, but with a significantly improved use and safety profile. These data substantially de-risk the program. The current valuation is dramatically understated." (3/1/2017)

Are investors shorting NeuroDerm?

NeuroDerm saw a increase in short interest in September. As of September 15th, there was short interest totalling 1,221,573 shares, an increase of 28.1% from the August 31st total of 953,489 shares. Based on an average daily volume of 530,756 shares, the short-interest ratio is currently 2.3 days. Approximately 6.0% of the company's stock are sold short.

Who are some of NeuroDerm's key competitors?

Who are NeuroDerm's key executives?

NeuroDerm's management team includes the folowing people:

  • Robert Taub, Chairman of the Board
  • Oded S. Liebermann, Chief Executive Officer, Director
  • Roy Golan CPA, Chief Financial Officer
  • Tami Yardeni, Chief Operating Officer
  • Sharon Cohen-Vered Ph.D., Vice President - CMC & QA
  • Sheila Oren, Vice President - Clinical and Regulatory Affairs
  • Eran Shor, Vice President - Devices
  • Oron Yacoby-Zeevi, Vice President - Research & Development
  • Revital Mandil-Levin Ph.D., Head - Business Development
  • Shmuel Cabilly, Director

When did NeuroDerm IPO?

(NDRM) raised $45 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 4,500,000 shares at $10.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Roth Capital Partners were co-managers.

Who owns NeuroDerm stock?

NeuroDerm's stock is owned by a number of of retail and institutional investors. Top institutional investors include Havens Advisors LLC (0.17%). View Institutional Ownership Trends for NeuroDerm.

Who bought NeuroDerm stock? Who is buying NeuroDerm stock?

NeuroDerm's stock was bought by a variety of institutional investors in the last quarter, including Havens Advisors LLC. View Insider Buying and Selling for NeuroDerm.

How do I buy NeuroDerm stock?

Shares of NeuroDerm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NeuroDerm's stock price today?

One share of NeuroDerm stock can currently be purchased for approximately $38.85.

MarketBeat Community Rating for NeuroDerm (NASDAQ NDRM)
Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about NeuroDerm and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for NeuroDerm (NASDAQ:NDRM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $45.86 (18.04% upside)
Consensus Price Target History for NeuroDerm (NASDAQ:NDRM)
Price Target History for NeuroDerm (NASDAQ:NDRM)
Analysts' Ratings History for NeuroDerm (NASDAQ:NDRM)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/14/2017Jefferies Group LLCReiterated RatingBuy$42.00LowView Rating Details
8/2/2017Roth CapitalDowngradeBuy -> Neutral$33.00 -> $39.00LowView Rating Details
7/24/2017Raymond James Financial, Inc.DowngradeOutperform -> Market Perform$39.00HighView Rating Details
7/21/2017Deutsche Bank AGInitiated CoverageBuy -> Buy$47.00HighView Rating Details
6/14/2017CIBCUpgradeMarket Perform -> Outperform$42.00HighView Rating Details
6/14/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> Outperform$42.00HighView Rating Details
3/7/2017Citigroup Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
3/1/2017Cowen and CompanyBoost Price TargetOutperform$38.00 -> $70.00N/AView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for NeuroDerm (NASDAQ:NDRM)
Earnings by Quarter for NeuroDerm (NASDAQ:NDRM)
Earnings History by Quarter for NeuroDerm (NASDAQ NDRM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.38)($0.25)ViewN/AView Earnings Details
3/30/201712/31/2016($0.46)($0.49)ViewN/AView Earnings Details
11/10/20169/30/2016($0.42)($0.42)ViewN/AView Earnings Details
8/25/2016Q2($0.32)($0.32)ViewListenView Earnings Details
5/26/2016Q1($0.35)($0.25)ViewListenView Earnings Details
3/31/2016Q4($0.29)($0.31)ViewListenView Earnings Details
11/11/2015Q315($0.34)($0.07)ViewListenView Earnings Details
8/6/2015Q215($0.20)($0.34)ViewListenView Earnings Details
5/27/2015Q115($0.28)($0.09)ViewListenView Earnings Details
4/2/2015Q4 2014($0.35)($2.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NeuroDerm (NASDAQ:NDRM)
2017 EPS Consensus Estimate: ($1.96)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.40)($0.40)($0.40)
Q2 20172($0.51)($0.40)($0.46)
Q3 20172($0.58)($0.50)($0.54)
Q4 20172($0.62)($0.50)($0.56)
(Data provided by Zacks Investment Research)


Dividend History for NeuroDerm (NASDAQ:NDRM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NeuroDerm (NASDAQ:NDRM)
No insider trades for this company have been tracked by


Headline Trends for NeuroDerm (NASDAQ:NDRM)
Latest Headlines for NeuroDerm (NASDAQ:NDRM)
Loading headlines, please wait.



NeuroDerm (NDRM) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.